Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C) Meeting Abstract
| Authors: | Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; Gandhi, M.; Mowat, R.; Shah, H.; Jurczak, W.; Re, A.; Hahn, U.; Prince, H. M.; Guo, W.; Ho, L.; Beck, R. C.; Yasenchak, C. A.; Lee, H. J. |
| Abstract Title: | Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C) |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 611 |
| Language: | English |
| ACCESSION: | WOS:001159306702124 |
| DOI: | 10.1182/blood-2023-172574 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
